Tags

Type your tag names separated by a space and hit enter

Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.
Virol Sin. 2010 Feb; 25(1):36-44.VS

Abstract

A group of SARS-like coronaviruses (SL-CoV) have been identified in horseshoe bats. Despite SL-CoVs and SARS-CoV share identical genome structure and high-level sequence similarity, SL-CoV does not bind to the same cellular receptor as for SARS-CoV and the N-terminus of the S proteins only share 64% amino acid identity, suggesting there are fundamental differences between these two groups of coronaviruses. To gain insight into the basis of this difference, we established a recombinant adenovirus system expressing the S protein from SL-CoV (rAd-Rp3-S) to investigate its immune characterization. Our results showed that immunized mice generated strong humoral immune responses against the SL-CoV S protein. Moreover, a strong cellular immune response demonstrated by elevated IFN-γ and IL-6 levels was also observed in these mice. However, the induced antibody from these mice had weaker cross-reaction with the SARS-CoV S protein, and did not neutralize HIV pseudotyped with SARS-CoV S protein. These results demonstrated that the immunogenicity of the SL-CoV S protein is distinct from that of SARS-CoV, which may cause the immunological differences between human SARS-CoV and bat SL-CoV. Furthermore, the recombinant virus could serve as a potential vaccine candidate against bat SL-CoV infection.

Authors+Show Affiliations

State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20960282

Citation

Hou, Yu-xuan, et al. "Immunogenicity of the Spike Glycoprotein of Bat SARS-like Coronavirus." Virologica Sinica, vol. 25, no. 1, 2010, pp. 36-44.
Hou YX, Peng C, Han ZG, et al. Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus. Virol Sin. 2010;25(1):36-44.
Hou, Y. X., Peng, C., Han, Z. G., Zhou, P., Chen, J. G., & Shi, Z. L. (2010). Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus. Virologica Sinica, 25(1), 36-44. https://doi.org/10.1007/s12250-010-3096-2
Hou YX, et al. Immunogenicity of the Spike Glycoprotein of Bat SARS-like Coronavirus. Virol Sin. 2010;25(1):36-44. PubMed PMID: 20960282.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus. AU - Hou,Yu-xuan, AU - Peng,Cheng, AU - Han,Zheng-gang, AU - Zhou,Peng, AU - Chen,Ji-guo, AU - Shi,Zheng-li, Y1 - 2010/02/12/ PY - 2009/08/24/received PY - 2009/10/28/accepted PY - 2010/10/21/entrez PY - 2010/10/21/pubmed PY - 2011/1/25/medline SP - 36 EP - 44 JF - Virologica Sinica JO - Virol Sin VL - 25 IS - 1 N2 - A group of SARS-like coronaviruses (SL-CoV) have been identified in horseshoe bats. Despite SL-CoVs and SARS-CoV share identical genome structure and high-level sequence similarity, SL-CoV does not bind to the same cellular receptor as for SARS-CoV and the N-terminus of the S proteins only share 64% amino acid identity, suggesting there are fundamental differences between these two groups of coronaviruses. To gain insight into the basis of this difference, we established a recombinant adenovirus system expressing the S protein from SL-CoV (rAd-Rp3-S) to investigate its immune characterization. Our results showed that immunized mice generated strong humoral immune responses against the SL-CoV S protein. Moreover, a strong cellular immune response demonstrated by elevated IFN-γ and IL-6 levels was also observed in these mice. However, the induced antibody from these mice had weaker cross-reaction with the SARS-CoV S protein, and did not neutralize HIV pseudotyped with SARS-CoV S protein. These results demonstrated that the immunogenicity of the SL-CoV S protein is distinct from that of SARS-CoV, which may cause the immunological differences between human SARS-CoV and bat SL-CoV. Furthermore, the recombinant virus could serve as a potential vaccine candidate against bat SL-CoV infection. SN - 1995-820X UR - https://www.unboundmedicine.com/medline/citation/20960282/Immunogenicity_of_the_spike_glycoprotein_of_bat_SARS_like_coronavirus_ L2 - https://dx.doi.org/10.1007/s12250-010-3096-2 DB - PRIME DP - Unbound Medicine ER -